A Widespread Population Study of Actual Medical Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia Across Europe and Beyond Official Clinical Guidelines
about
Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptomsA pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: a Korean nationwide health insurance database study.Urolift: a new chapter in benign prostate hyperplasia (BPH) therapy.An overview of prostate diseases and their characteristics specific to Asian men.Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia.The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy.Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.Effect of Discontinuation of Tamsulosin in Korean Men with Benign Prostatic Hyperplasia Taking Tamsulosin and Dutasteride: An Open-Label, Prospective, Randomized Pilot Study.Medical management of benign prostatic hyperplasia: Results from a population-based study.Urolift - minimally invasive surgical BPH management.Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study).Are men on 5α-reductase inhibitors appropriately referred to urology? A survey of primary care physicians.Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the manageActual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.Comparison of Visual Prostate Symptom Score and International Prostate Symptom Score in the evaluation of men with benign prostatic hyperplasia: A prospective study from an Indian population.Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.Patient centred care for the medical treatment of lower urinary tract symptoms in patients with benign prostatic obstruction: a key point to improve patients' care - a systematic review.
P2860
Q21256691-803CC243-FF32-4D25-8EB2-3CB47B6EE1DDQ30764782-3A5BE038-F58B-4D9A-8E97-5A83C8C9573FQ30843218-F9D94C9F-32FF-4397-812B-ECFD080C9705Q35164829-1E4FD4BA-85DA-48D5-89F0-972A6793EE00Q36790080-67A854F6-C232-4433-A486-6C0E034D588CQ37037794-316B52CB-F7FE-4B53-85A1-A77D9D3E26CCQ38051005-C6D2B23A-E287-4DF5-9E80-97DBCCC7F71FQ38241547-D0D7BABD-518D-4FB6-9553-9FA3FC6E8101Q38259866-F6609102-DC9A-4272-BFFD-4E796B899FC8Q38313282-27B1F5C0-AE10-4195-B5BE-7873AA5973D6Q38466939-9C29E728-AFBC-4C25-9DD8-DFEF2E666805Q38682496-DDCACE80-198F-4D25-975F-CC7636F5D01FQ39166801-89B0069E-E01A-40FF-9151-E237241899C5Q39266416-4AFF5B83-4303-41EF-93EF-26C602B34F48Q39926524-DBE33875-0CA7-4AC7-8988-DA31EE235C03Q39965082-FD9190A4-DD54-4278-A1E7-4DAA7FC19004Q43902268-91FF87F8-8AAD-4CE8-ACED-DBAC70BC1FD7Q45785775-29DF5C8E-C8CA-4D89-80B9-5EF55D731431Q47098578-96F90F20-02AC-4695-8360-6DD7EE06E997Q47434739-886F58AC-E7AC-493C-A7C9-FBAE8B640EBBQ53110726-EEA3673C-67E7-424B-B999-C4AE1EB3D04CQ55437967-174613D7-2915-457F-9CC5-20612ADB5C76
P2860
A Widespread Population Study of Actual Medical Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia Across Europe and Beyond Official Clinical Guidelines
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2010
@uk
name
A Widespread Population Study ...... d Official Clinical Guidelines
@en
A Widespread Population Study ...... d Official Clinical Guidelines
@nl
type
label
A Widespread Population Study ...... d Official Clinical Guidelines
@en
A Widespread Population Study ...... d Official Clinical Guidelines
@nl
prefLabel
A Widespread Population Study ...... d Official Clinical Guidelines
@en
A Widespread Population Study ...... d Official Clinical Guidelines
@nl
P2093
P1433
P1476
A Widespread Population Study ...... d Official Clinical Guidelines
@en
P2093
Bertrand Lukacs
François Haab
Jean-Nicolas Cornu
P304
P356
10.1016/J.EURURO.2010.05.045
P407
P577
2010-09-01T00:00:00Z